Pharmacist Focused Strategies for Systemic Mastocytosis

CE

Systemic Mastocytosis: Pharmacist-Focused Strategies to Improve Outcomes

Pharmacists: 1.00 contact hour (0.1 CEUs)

Released: May 22, 2025

Expiration: May 21, 2026

Activity

Progress
1 2
Course Completed

Introduction

In this module, Jonathan A. Bernstein, MD, and Ryan Haumschild, PharmD, MS, MBA, CPEL, discuss the clinical presentation of patients with systemic mastocytosis (SM), diagnostic criteria for SM and its subtypes, guideline-directed SM management, and current and emerging therapies that target underlying pathologic processes.

The key points discussed in this module are illustrated with thumbnails from the accompanying downloadable PowerPoint slidesets, which can be accessed here or by clicking any of the slide thumbnails in the module alongside the expert commentary.

Clinical Care Options plans to measure the educational impact of this activity. Some questions will be asked twice, at the beginning and the end of the activity. Your responses will be aggregated for analysis, and your specific responses will not be shared.

Before continuing with this educational activity, please take a moment to answer the following questions.

How many people with systemic mastocytosis (SM) do you provide care for in a typical month?

You are doing a medication reconciliation, and you identify that the patient is receiving treatment for osteoporosis, migraine, and frequent diarrhea.

Based on this information, which is the most appropriate statement regarding the need to evaluate the patient for SM?

Your patient has indolent SM with KIT D816V mutation and initially found relief for itching and diarrhea with antimediator therapies, but after 6 months the symptoms are worsening. 

Based on the PIONEER trial, which is the most accurate information you can give your patient on the duration of symptom benefits observed with the selective KIT inhibitor avapritinib? 

In educating patients with SM on epinephrine use, which of the following represents correct information that you could provide when discussing their anaphylaxis risk?

How often do you educate patients who have an epinephrine prescription on the need for a treatment plan that outlines when epinephrine should be used?